Paris (France), December 9, 2019 – 05:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers, today announced its financial agenda for 2020.

Event Date*
Full-year 2019 results Tuesday, March 31, 2020
Shareholders’ general meeting Wednesday, May 13, 2020
Half-year 2020 results Thursday, September 17, 2020


* This preliminary agenda may be modified. Press releases are published after financial markets close.